ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• ANI Pharmaceuticals has a consensus analyst rating of “Moderate Buy” from eight covering firms, with an average 12-month price target of about $107.33.
• The company delivered a strong quarterly beat, posting $2.05 EPS versus $1.28 expected and $237.46 million in revenue versus $207.63 million expected, while revenue rose 20.5% year over year.
• Management also raised FY 2026 EPS guidance to $9.19–$9.69, signaling confidence in continued profitability; revenue guidance was roughly in line with expectations.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $107.3333.

A number of research analysts have commented on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, April 15th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Guggenheim upped their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a "buy" rating in a research report on Friday, January 16th.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $81.86 on Monday. ANI Pharmaceuticals has a 52-week low of $56.71 and a 52-week high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm's fifty day moving average is $76.82 and its two-hundred day moving average is $81.01. The stock has a market cap of $1.83 billion, a PE ratio of 20.72 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts' expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm's quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals will post 7.64 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 3,162 shares of the company's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $71.64, for a total transaction of $226,525.68. Following the sale, the insider directly owned 91,309 shares in the company, valued at approximately $6,541,376.76. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president directly owned 38,730 shares of the company's stock, valued at $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 27,860 shares of company stock valued at $2,111,581. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock worth $103,022,000 after acquiring an additional 27,598 shares in the last quarter. State Street Corp raised its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company's stock worth $57,405,000 after buying an additional 15,496 shares during the last quarter. UBS Group AG increased its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock worth $40,843,000 after purchasing an additional 43,523 shares in the last quarter. Finally, Tang Capital Management LLC increased its position in ANI Pharmaceuticals by 51.6% during the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company's stock worth $38,005,000 after purchasing an additional 163,937 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.